Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Efinaconazole Topical Solution, 10%, used to treat toenail fungal infections. The approval is therapeutically equivalent to Bausch Health's brand Jublia. Alembic was among the first companies to file this generic with a Paragraph IV patent challenge, which could give it 180 days of marketing exclusivity in the US. The reference product has an estimated US market size of around US$ 500 million (12 months ending December 2025, per IQVIA). With this, Alembic's cumulative ANDA tally from USFDA rises to 234 (215 final + 19 tentative).
Positive for the stock — the approval opens up access to a sizeable US$500M addressable market, and Paragraph IV status may allow Alembic to capture early share with potential exclusivity benefits, supporting future US revenue growth.